Equity Overview
Price & Market Data
Price: $0.558
Daily Change: -$0.0533 / 9.56%
Range: $0.554 - $0.61
Market Cap: $15,254,287
Volume: 2,590
Performance Metrics
1 Week: 13.21%
1 Month: 17.45%
3 Months: -25.49%
6 Months: -35.00%
1 Year: -82.37%
YTD: -16.31%
Company Details
Employees: 57
Sector: Health technology
Industry: Biotechnology
Country: Israel
Details
BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. It also developing BX004, a phage therapy for cystic fibrosis and non-cystic fibrosis bronchiectasis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. The company was founded in 2015 and is headquartered in Ness Ziona, Israel.